Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.55 |
| ▸ | EGLN3 | Q9H6Z9 | 9/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 8/20 | 0.53 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 6/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513713 | 0.89 | EGLN1 (0.68) | EGLN1EGLN3EGLN2CYSLTR2CNR2 | |
| SCHEMBL13437414 | 0.82 | EGLN1 (0.81) | EGLN1EGLN3EGLN2CYSLTR2CNR2 | |
| SCHEMBL3514782 | 0.81 | EGLN1 (0.45) | EGLN1EGLN3EGLN2CNR2 | |
| SCHEMBL2576293 | 0.81 | EGLN1 (0.42) | EGLN1 | |
| SCHEMBL13437408 | 0.77 | EGLN1 (0.61) | EGLN1EGLN3EGLN2CNR2CNR1 | |
| SCHEMBL3513398 | 0.77 | EGLN1 (0.65) | EGLN1EGLN3EGLN2CYSLTR2CNR2 | |
| SCHEMBL17629567 | 0.76 | EGLN1 (0.78) | EGLN1EGLN3EGLN2CYSLTR2 | |
| SCHEMBL2086450 | 0.75 | EGLN1 (0.63) | EGLN1EGLN3EGLN2CYSLTR2CNR2 | |
| SCHEMBL12913726 | 0.75 | EGLN1 (0.67) | EGLN1EGLN3EGLN2CYSLTR2 | |
| SCHEMBL3773677 | 0.75 | EGLN1 (0.79) | EGLN1EGLN3EGLN2CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
| EP-2136810-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008130527-A1 | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056563-A1 | NOVEL 1.8-NAPHTHYRIDINE COMPOUNDS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885EGLN3 4/4885EGLN2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.